Both soluble and membrane-bound forms of Flt3 ligand enhance tumor immunity following "suicide" gene therapy in a murine colon carcinoma model

Cancer Immunology, Immunotherapy

Volumn 53, Issue 11, 2004, Pages 946-954

  Alsheikhly, Abdul Razzak ^a   Zweiri, Jehad ^a   Walmesley, Alice J ^a   Watson, Alastair J M ^a   Christmas, Stephen E ^a  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Colon carcinoma; Flt3 ligand; GM CSF; Immunotherapy; MC26; Suicide gene therapy

Indexed keywords

FLT3 LIGAND; GANCICLOVIR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; PRODRUG; THYMIDINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTING CELL; ARTICLE; CELL KILLING; CELL PROLIFERATION; CELL STIMULATION; COLON CARCINOMA; CONTROLLED STUDY; DENDRITIC CELL; DRUG EFFECT; FEMALE; GENE THERAPY; GENETIC TRANSFECTION; GROWTH INHIBITION; HERPES SIMPLEX VIRUS 1; IMMUNE RESPONSE; MEMBRANE BINDING; MOUSE; NONHUMAN; PRIORITY JOURNAL; SUICIDE GENE THERAPY; TUMOR GROWTH; TUMOR IMMUNITY; TUMOR RECURRENCE; WILD TYPE;

ANIMALS; CARCINOMA; CELL DIVISION; CELL LINE, TUMOR; CELL MEMBRANE; COLONIC NEOPLASMS; DENDRITIC CELLS; DISEASE MODELS, ANIMAL; FEMALE; GANCICLOVIR; GENE THERAPY; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HERPESVIRUS 1, HUMAN; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; PRODRUGS; RECURRENCE; SPLEEN; THYMIDINE KINASE; TIME FACTORS; TRANSFECTION;

EID: 5644224491     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00262-004-0553-5     Document Type: Article

References (42)

1. Alsheikhly AR (1994) Interaction of in vitro- and in vivo-generated cytotoxic T cells with SV40 T antigen: analysis with synthetic peptides. Scand J Immunol 39:467
2. Averbook BJ, Schuh JL, Papay R, Maliszewski C (2002) Antitumor effects of Flt3 ligand in transplanted murine tumor models. J Immunother 25:27
3. Bjorck P (2001) Isolation and characterization of plasmacytoid dendritic cells from Flt3 ligand and granulocyte-macrophage colony-stimulating factor-treated mice. Blood 98:3520
4. Cao X, Huang X, Ju DW, Zhang W, Hamada H, Wang J (2000) Enhanced antitumoral effect of adenovirus-mediated cytosine deaminase gene therapy by induction of antigen-presenting cells through stem cell factor/granulocyte- macrophage colony-stimulating factor gene transfer. Cancer Gene Ther 7:177
5. Caruso M, Panis Y, Gagandeep S, Houssin D, Salzmann JL, Klatzmann D (1993) Regression of established macroscopic liver metastases after in situ transduction of a suicide gene. Proc Natl Acad Sci U S A 90:7024
6. Caruso M, Pham-Nguyen K, Kwong YL, Xu B, Kosai KI, Finegold M, Woo SL, Chen SH (1996) Adenovirus-mediated interleukin-12 gene therapy for metastatic colon carcinoma. Proc Natl Acad Sci U S A 93:11302
7. Chen K, Braun S, Lyman S, Fan Y, Traycoff CM, Wiebke EA, Gaddy J, Sledge G, Broxmeyer HE, Cornetta K (1997) Antitumor activity and immunotherapeutic properties of Flt3-ligand in a murine breast cancer model. Cancer Res 57:3511
8. Chiodoni C, Paglia P, Stoppacciaro A, Rodolfo M, Parenza M, Colombo MP (1999) Dendritic cells infiltrating tumors cotransduced with granulocyte/macrophage colony-stimulating factor (GM-CSF) and CD40 ligand genes take up and present endogenous tumor-associated antigens, and prime naive mice for a cytotoxic T lymphocyte response. J Exp Med 190:125
9. Ciavarra RP, Brown RR, Holterman DA, Garrett M, Glass WF 2nd, Wright GL Jr, Schellhammer PF, Somers KD (2003) Impact of the tumor microenvironment on host infiltrating cells and the efficacy of flt3-ligand combination immunotherapy evaluated in a treatment model of mouse prostate cancer. Cancer Immunol Immunother 52:535
10. Diaz RM, Todryk S, Chong H, Hart IR, Sikora K, Dorudi S, Vile RG (1998) Rapid adenoviral transduction of freshly resected tumour explants with therapeutically useful genes provides a rationale for genetic immunotherapy for colorectal cancer. Gene Ther 5:869
11. Dong J, Bohinski RJ, Li YQ, Van Waes C, Hendler F, Gleich L, Stambrook PJ (2003) Antitumor effect of secreted Flt3-ligand can act at distant tumor sites in a murine model of head and neck cancer. Cancer Gene Ther 10:96
12. Favre-Felix N, Martin M, Maraskovsky E, Fromentin A, Moutet M, Solary E, Martin F, Bonnotte B (2000) Flt3 ligand lessens the growth of tumors obtained after colon cancer cell injection in rats but does not restore tumor-suppressed dendritic cell function. Int J Cancer 86:827
13. Gagandeep S, Brew R, Green B, Christmas SE, Klatzmann D, Poston GJ, Kinsella AR (1996) Prodrug-activated gene therapy: involvement of an immunological component in the "bystander effect". Cancer Gene Ther 3:83
14. Gilliet M, Boonstra A, Paturel C, Antonenko S, Xu XL, Trinchieri G, O'Garra A, Liu YJ (2002) The development of murine plasmacytoid dendritic cell precursors is differentially regulated by FLT3-ligand and granulocyte/macrophage colony-stimulating factor. J Exp Med 195:953
15. Golumbek PT, Hamzeh FM, Jaffee EM, Levitsky H, Lietman PS, Pardoll DM (1992) Herpes simplex-1 virus thymidine kinase gene is unable to completely eliminate live, nonimmunogenic tumor cell vaccines. J Immunother 12:224
16. Hannum C, Culpepper J, Campbell D, McClanahan T, Zurawski S, Bazan JF, Kastelein R, Hudak S, Wagner J, Mattson J et al (1994) Ligand for FLT3/FLK2 receptor tyrosine kinase regulates growth of haematopoietic stem cells and is encoded by variant RNAs. Nature 368:643
17. Howard BD, Kalthoff H, Fong TC (1999) Ablation of tumor cells in vivo by direct injection of HSV-thymidine kinase retroviral vector and ganciclovir therapy. Ann N Y Acad Sci 880:352
18. Huang AY, Gulden PH, Woods AS, Thomas MC, Tong CD, Wang W, Engelhard VH, Pasternack G, Cotter R, Hunt D, Pardoll DM, Jaffee EM (1996) The immunodominant major histocompatibility complex class I-restricted antigen of a murine colon tumor derives from an endogenous retroviral gene product. Proc Natl Acad Sci U S A 93:9730
19. Jalili A, Stoklosa T, Giermasz A, Olszewska D, Wilczynski G, Jakobisiak M, Golab J (2002) A single injection of immature dendritic cells is able to induce antitumour response against a murine colon adenocarcinoma with a low apoptotic index. Oncol Rep 9:991
20. Jones RK, Pope IM, Kinsella AR, Watson AJ, Christmas SE (2000) Combined suicide and granulocyte-macrophage colony-stimulating factor gene therapy induces complete tumor regression and generates antitumor immunity. Cancer Gene Ther 7:1519
21. Kershaw MH, Hsu C, Mondesire W, Parker LL, Wang G, Overwijk WW, Lapointe R, Yang JC, Wang RF, Restifo NP, Hwu P (2001) Immunization against endogenous retroviral tumor-associated antigens. Cancer Res 61:7920
22. Kielian T, Nagai E, Ikubo A, Rasmussen CA, Suzuki T (1999) Granulocyte/macrophage-colony-stimulating factor released by adenovirally transduced CT26 cells leads to the local expression of macrophage inflammatory protein lalpha and accumulation of dendritic cells at vaccination sites in vivo. Cancer Immunol Immunother 48:123
23. Kim EM, Sivanandham M, Stavropoulos CI, Wallack MK (2002) Adjuvant effect of a Flt3 ligand (FL) gene-transduced xenogeneic cell line in a murine colon cancer model. J Surg Res 108:148
24. Lyman SD, James L, Bos TV, de Vries P, Brasel K, Gliniak B, Hollingsworth LT, Picha KS, McKenna HJ, Splett RR, Fletcher FA, Maraskovsky E, Farrah T, Foxworthe D, Williams DE, Beckmann MP (1993) Molecular cloning of a ligand for the flt3/flk-2 tyrosine kinase receptor: a proliferative factor for primitive hematopoetic cells. Cell 75:1157
25. Lyman SD, James L, Escobar S, Downey H, de Vries P, Brasel K, Stocking K, Beckmann MP, Copeland NG, Cleveland LS et al (1995) Identification of soluble and membrane-bound isoforms of the murine flt3 ligand generated by alternative splicing of mRNAs. Oncogene 10:149
26. Lynch DH, Andreasen A, Maraskovsky E, Whitmore J, Miller RE, Schuh JC (1997) Flt3 ligand induces tumor regression and antitumor immune responses in vivo. Nat Med 3:625
27. Mach N, Gillessen S, Wilson SB, Sheehan C, Mihm M, Dranoff G (2000) Differences in dendritic cells stimulated in vivo by tumors engineered to secrete granulocyte-macrophage colony-stimulating factor or Flt3-ligand. Cancer Res 60:3239
28. Marroquin CE, Westwood JA, Lapointe R, Mixon A, Wunderlich JR, Caron D, Rosenberg SA, Hwu P (2002) Mobilization of dendritic cell precursors in patients with cancer by flt3 ligand allows the generation of higher yields of cultured dendritic cells. J Immunother 25:278
29. McClanahan T, Culpepper J, Campbell D, Wagner J, Franz-Bacon K, Mattson J, Tsai S, Luh J, Guimaraes MJ, Mattei MG, Rosnet O, Birnbaum D, Hannum CH (1996) Biochemical and genetic characterization of multiple splice variants of the Flt3 ligand. Blood 88:3371
30. Miller G, Pillarisetty VG, Shah AB, Lahrs S, DeMatteo RP (2003) Murine Flt3 ligand expands distinct dendritic cells with both tolerogenic and immunogenic properties. J Immunol 170:3554
31. Moghaddami M, Swart B, Reynolds P, Diener K, Brown MP (2002) Flt3 ligand expands dendritic cell numbers in normal and malignant murine prostate. Immunol Cell Biol 80:370
32. Moolten FL (1986) Tumor chemosensitivity conferred by inserted herpes thymidine kinase genes: paradigm for a prospective cancer control strategy. Cancer Res 46:5276
33. Mosca PJ, Hobeika AC, Colling K, Clay TM, Thomas EK, Caron D, Lyerly HK, Morse MA (2002) Multiple signals are required for maturation of human dendritic cells mobilized in vivo with Flt3 ligand. J Leukoc Biol 72:546
34. Shaw SG, Maung AA, Steptoe RJ, Thomson AW, Vujanovic NL (1998) Expansion of functional NK cells in multiple tissue compartments of mice treated with Flt3-ligand: implications for anti-cancer and anti-viral therapy. J Immunol 161:2817
35. Sivanandham M, Stavropoulos CI, Kim EM, Mancke B, Wallack MK (2002) Therapeutic effect of colon tumor cells expressing FLT-3 ligand plus systemic IL-2 in mice with syngeneic colon cancer. Cancer Immunol Immunother 51:63
36. Stoppacciaro A, Paglia P, Lombardi L, Parmiani G, Baroni C, Colombo MP (1997) Genetic modification of a carcinoma with the IL-4 gene increases the influx of dendritic cells relative to other cytokines. Eur J Immunol 27:2375
37. Tong Y, Song W, Crystal RG (2001) Combined intratumoral injection of bone marrow-derived dendritic cells and systemic chemotherapy to treat pre-existing murine tumors. Cancer Res 61:7530
38. Vile RG, Nelson JA, Castleden S, Chong H, Hart IR (1994) Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res 54:6228
39. Vile RG, Castleden S, Marshall J, Camplejohn R, Upton C, Chong H (1997) Generation of an anti-tumour immune response in a non-immunogenic tumour: HSVtk killing in vivo stimulates a mononuclear cell infiltrate and a Th1-like profile of intratumoural cytokine expression. Int J Cancer 71:267
40. Vile RG, Russell SJ, Lemoine NR (2000) Cancer gene therapy: hard lessons and new courses. Gene Ther 7:2
41. Wang A, Braun SE, Sonpavde G, Cornetta K (2000) Antileukemic activity of Flt3 ligand in murine leukemia. Cancer Res 60:1895
42. Yu H, Fehniger TA, Fuchshuber P, Thiel KS, Vivier E, Carson WE, Caligiuri MA (1998) Flt3 ligand promotes the generation of a distinct CD34(+) human natural killer cell progenitor that responds to interleukin-15. Blood 92:3647